ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Advances in quercetin-based therapeutics for breast cancer: natural, synthetic, and nanotechnology-driven approaches.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Targeted Mechanisms of Phytochemicals in Mitigating Cadmium-Induced Breast Cancer.Medicines (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide, despite significant advances in early detection and treatment. Conventional chemotherapeutic agents often face limitations such as drug resistance, off-target toxicity, and poor patient adherence. These challenges have highlighted the need for safer, more effective alternatives. Naturally derived compounds, especially flavonoids such as quercetin, have recently attracted attention for their ability to modulate key cancer pathways with minimal side effects. This review critically examines natural quercetin and its metabolites in the context of breast cancer prevention and treatment, focusing on their molecular targets and pharmacodynamic effects. To address issues such as poor bioavailability and rapid metabolism, we also discuss the design and synthesis of quercetin derivatives that exhibit improved stability, solubility, and targeted delivery. Additionally, the review highlights emerging quercetin-based nanomaterials designed to enhance therapeutic precision. This review offers a comprehensive overview of the development of quercetin-based therapies, outlining current progress, identifying translational hurdles, and proposing future directions for the development of optimized, targeted, and clinically viable quercetin formulations for breast cancer treatment.
Indexed as
Identifiers
42446692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.